Genmab A/S (NASDAQ:GMAB) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 16, Genmab A/S announced new sales figures for DARZALEX as of the second quarter of 2025.
The company reported that the total worldwide sales reached $3.539 billion. Out of this, the US sales accounted for $2.017 billion, whereas sales from the rest of the world reached $1.521 billion. Management noted that the DARZALEX includes both intravenous and subcutaneous forms. Moreover, Genmab A/S does not sell DARZALEX directly; instead, Johnson & Johnson holds the exclusive license to develop and commercialize the drug, and the company receives royalties based on the sales.
A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.
Genmab A/S is a biotechnology company from Denmark that develops antibody-based medicines to treat cancer and other diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
